Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat Plus Hydroxychloroquine in Relapsed or Refractory Clear Cell Sarcoma
NCT04593758Phase 2Completed
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of devimistat in clear cell sarcoma of soft tissue (CCS), sponsored by Cornerstone Pharmaceuticals. Primary endpoints: Maximally Tolerated Dose at 6 months, Toxicity Profile at 6 months and 1 more. Started Sep 2021; status: completed.
02
Drugs
devimistat
03
Conditions
clear cell sarcoma of soft tissue (CCS)
Beyond the preview
Go deeper on NCT04593758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593758.